Nebenwirkungen · Osenvelt
Osenvelt 120 mg solution for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-151795 · Präparat HOS-100625
Hypocalcaemia has very commonly been reported following denosumab administration, mostly within the first 2 weeks. Hypocalcaemia can be severe and symptomatic (see section 4.8 - description of selected adverse reactions). The decreases in serum calcium were generally appropriately managed by calcium and vitamin D supplementation. The most common adverse reactions with denosumab are musculoskeletal pain. Cases of osteonecrosis of the jaw (see sections 4.4 and 4.8 - description of selected adverse reactions) have been commonly observed in patients taking denosumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T16:45:00Z · SHA-256 ad230d7aaf80f3cf993a5e59ca1d6e376e97d797e41645778c0fbd8b978725a6 · Passage 3edf35e8a882bf4ade9af189aec5bd9abf604d9acc7bb5b379309b0b4f176cb4 · Zeichen 112–681 im Abschnitt